Company research
Microbot Medical Inc.
CIK 883975Updated Nov 18, 2026
MBOT price & chart
Loading TradingView…
NASDAQ:MBOT on TradingView ↗About the company
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical® is available at http://www.microbotmedical.com.
In the news
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
ARS filing
DEFA14A filing
Show 5 more recent filings
DEF 14A filing
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Shareholder Director Nominations · Regulation FD Disclosure
Items 5.08, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 81,760,000Source | 5,208,000Source | 73,365,000Source | 33,131,000Source | 7,434,000Source | 78,066,000Source | 30,892,000Source | 7,367,000Source | 81,544,000Source | 6,031,000Source | 8,327,000Source | 9,537,000Source |
| Property, Plant and Equipment, NetUSD | 78,000Source | 99,000Source | 316,000Source | 75,000Source | 122,000Source | 188,000Source | 78,000Source | 132,000Source | 93,000Source | 80,000Source | 146,000Source | 221,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,704,000Source | 479,000Source | 3,152,000Source | 4,082,000Source | 2,465,000Source | 3,657,000Source | 3,217,000Source | 1,162,000Source | 3,912,000Source | 3,114,000Source | 2,468,000Source | 2,442,000Source |
| Inventory, NetUSD | — | — | 2,907,000Source | — | — | 2,257,000Source | — | — | 584,000Source | — | — | — |
| Assets, CurrentUSD | 80,785,000Source | 4,995,000Source | 72,173,000Source | 32,891,000Source | 7,138,000Source | 76,528,000Source | 30,656,000Source | 7,000,000Source | 79,822,000Source | 5,819,000Source | 7,921,000Source | 8,814,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 573,000Source | 609,000Source | 709,000Source | 164,000Source | 628,000Source | 660,000Source | 218,000Source | 603,000Source | 644,000Source | 300,000Source | 152,000Source | 532,000Source |
| Operating Lease, Right-of-Use AssetUSD | 897,000Source | 114,000Source | 800,000Source | 165,000Source | 174,000Source | 870,000Source | 158,000Source | 235,000Source | 833,000Source | 132,000Source | 260,000Source | 502,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 3,536,000Source | 1,400,000Source | 4,438,000Source | 2,774,000Source | 1,379,000Source | 3,961,000Source | 1,941,000Source | 1,200,000Source | 3,990,000Source | 2,501,000Source | 3,826,000Source | 2,248,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 659,000Source | 168,000Source | 672,000Source | 380,000Source | 161,000Source | 672,000Source | 348,000Source | 145,000Source | 672,000Source | 195,000Source | 118,000Source | 80,000Source |
| Retained Earnings (Accumulated Deficit)USD | -100,622,000Source | -87,552,000Source | -113,384,000Source | -97,045,000Source | -84,337,000Source | -107,757,000Source | -93,545,000Source | -81,872,000Source | -104,086,000Source | -90,944,000Source | -79,501,000Source | -68,761,000Source |
| Stockholders' Equity Attributable to ParentUSD | 78,224,000Source | 3,808,000Source | 68,927,000Source | 30,357,000Source | 6,055,000Source | 74,105,000Source | 28,951,000Source | 6,167,000Source | 77,554,000Source | 3,530,000Source | 4,501,000Source | 7,289,000Source |
| Additional Paid in Capital, Common StockUSD | 178,187,000Source | 91,192,000Source | 181,639,000Source | 127,022,000Source | 90,231,000Source | 181,190,000Source | 122,148,000Source | 87,894,000Source | 180,968,000Source | 94,279,000Source | 83,884,000Source | 75,970,000Source |
| Liabilities and EquityUSD | 81,760,000Source | 5,208,000Source | 73,365,000Source | 33,131,000Source | 7,434,000Source | 78,066,000Source | 30,892,000Source | 7,367,000Source | 81,544,000Source | 6,031,000Source | 8,327,000Source | 9,537,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,934,000Source | 1,371,000Source | 3,888,000Source | 2,727,000Source | 1,341,000Source | 3,387,000Source | 1,893,000Source | 1,183,000Source | 3,421,000Source | 2,460,000Source | 3,786,000Source | 2,069,000Source |
| Operating Lease, Liability, CurrentUSD | 297,000Source | 65,000Source | 326,000Source | 102,000Source | 110,000Source | 324,000Source | 90,000Source | 191,000Source | 296,000Source | 70,000Source | 191,000Source | 283,000Source |
| Accounts Payable, CurrentUSD | 509,000Source | 246,000Source | 871,000Source | 503,000Source | 178,000Source | 1,085,000Source | 186,000Source | 96,000Source | 511,000Source | — | — | 116,000Source |
| Operating Lease, Liability, NoncurrentUSD | 602,000Source | 29,000Source | 550,000Source | 47,000Source | 38,000Source | 574,000Source | 48,000Source | 17,000Source | 569,000Source | 41,000Source | 40,000Source | 179,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,128,000Source | 1,060,000Source | 2,691,000Source | 2,122,000Source | 1,053,000Source | 1,978,000Source | 1,617,000Source | 896,000Source | 2,614,000Source | 2,225,000Source | 1,027,000Source | 1,670,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 80,158,000Source | 4,338,000Source | 67,367,000Source | 32,674,000Source | 6,462,000Source | 72,500,000Source | 30,390,000Source | 6,349,000Source | 78,592,000Source | 5,470,000Source | 6,385,000Source | 8,202,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 191,000Source | 30,000Source | 357,000Source | 114,000Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 12,000Source | 15,000Source | 47,000Source | 91,000Source | 106,000Source | 102,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | 433,000Source | 237,000Source | 222,000Source | 256,000Source | 1,057,000Source | 1,349,000Source | 1,394,000Source | 1,752,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 1,673,000Source | — | 584,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,053,000Source | -2,874,000Source | -13,046,000Source | -8,827,000Source | -8,533,000Source | -11,549,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 4,997,000Source | -24,830,000Source | -72,384,000Source | 1,537,000Source | 1,973,000Source | -3,836,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | -3,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 108,000Source | 13,000Source | 60,000Source | 25,000Source | 33,000Source | 84,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 27,806,000Source | 86,240,000Source | 7,936,000Source | 6,558,000Source | 4,324,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -56,000Source | 102,000Source | 810,000Source | 646,000Source | -2,000Source | -11,061,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 171,000Source | 130,000Source | 51,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,752,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 80,158,000Source | 4,338,000Source | 67,367,000Source | 32,674,000Source | 72,500,000Source | 30,390,000Source | 78,592,000Source | 5,470,000Source | 6,385,000Source | 8,202,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | -2,000Source | -5,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | -1,111,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,690,000Source | 1,240,000Source | — | 1,612,000Source | — | 1,562,000Source | — | 4,995,000Source | 4,131,000Source | 5,545,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | 222,000Source | — | 4,000Source | 0Source | 59,000Source | 12,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,577,000Source | -3,215,000Source | -5,627,000Source | -3,500,000Source | -3,671,000Source | -2,601,000Source | -13,142,000Source | -11,443,000Source | -10,740,000Source | -13,168,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | 316,000Source | — | — | — | -5,000Source |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | — | — | 3,684,000Source | 1,612,000Source | 3,029,000Source | 1,562,000Source | 8,460,000Source | — | — | — |
| Operating Income (Loss)USD | — | — | -3,861,000Source | -3,300,000Source | -6,188,000Source | -3,723,000Source | -4,320,000Source | -3,021,000Source | -14,743,000Source | -11,625,000Source | -9,855,000Source | -13,281,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | 316,000Source | — | — | — | -5,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,577,000Source | -3,215,000Source | -5,627,000Source | -3,500,000Source | -3,671,000Source | -2,601,000Source | -13,142,000Source | -11,443,000Source | -10,740,000Source | -13,168,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.07Source | -0.2Source | -0.08Source | -0.1Source | -0.05Source | -0.08Source | -0.29Source | -0.73Source | -1.05Source | -1.81Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.07Source | -0.2Source | -0.08Source | -0.1Source | -0.05Source | -0.08Source | -0.29Source | -0.73Source | -1.05Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 48,095,384Source | 16,471,419Source | 67,163,613Source | 36,488,014Source | 67,158,044Source | 31,085,606Source | 45,790,362Source | 15,644,511Source | 10,199,984Source | 7,260,344Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 48,095,384Source | 16,471,419Source | 67,163,613Source | 36,488,014Source | 67,158,044Source | 31,085,606Source | 45,790,362Source | 15,644,511Source | 10,199,984Source | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 4,562,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | -1,111,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,690,000Source | 1,240,000Source | — | 1,612,000Source | — | 1,562,000Source | — | 4,995,000Source | 4,131,000Source | 5,545,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 284,000Source | 85,000Source | 561,000Source | 223,000Source | 649,000Source | 104,000Source | 1,285,000Source | 182,000Source | 228,000Source | 118,000Source |
| Labor and Related ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 2,067,000Source |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | — | 239,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 1,171,000Source | 2,060,000Source | 1,861,000Source | 2,111,000Source | 1,293,000Source | 1,459,000Source | 6,283,000Source | 6,630,000Source | 5,724,000Source | 7,736,000Source |
| Total Revenue | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Cost of Goods and Services Sold | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Gross Profit | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
Offerings
Registration 333-284688
Filing attachments
ex99-1.htm · 8-K · 2026-11-16
Exhibit 99.1 Microbot Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements Company continues to expand commercial presence in the U.S. while it progresses international market entry and opportunities Increased the number of health systems and hospital sites using LIBERTY, while utilization of the LIBERTY System rose 44% compared to the second quarter HINGHAM, Mass., November 16, 2026 - Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LI…
Read attachment ↗ex99-1.htm · 8-K · 2026-11-05
Exhibit 99.1 Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion HINGHAM, Mass., November 5, 2026 - Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that the Canadian Intellectual Property Office (CIPO) granted the Company a patent for an adaptor for coupling a proximal portion of an elongate surgical tool (guidewire, microcathe…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-27
Exhibit 99.1 Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company’s Full Market Release strategy. The Company believes the OBLs represent a rapidly growing healthcare segment and opportunity as many endovascular procedures are being done outside traditional hospital settings and Ambulatory Surgery Centers. HINGHAM, …
Read attachment ↗ex99-1.htm · 8-K · 2026-10-23
Exhibit 99.1 Microbot Medical® Attending Key Medical Conference to Engage with Decisionmakers as it Continues to Expand Presence Across the U.S. Opportunity to Connect with Hospital Administrators and Physicians to Foster Expanded Adoption of the LIBERTY System HINGHAM, Mass., October 23, 2026 - Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, today announced that key executives and members of the Company’s commercial tea…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-20
Exhibit 99.1 Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international markets. HINGHAM, Mass., October 20, 2026 - Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has received several new patent approvals …
Read attachment ↗ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S. HINGHAM, Mass., October 6, 2026 -- Microbot Medi…
Read attachment ↗